Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3477520 | 1.00 | PLG (0.32) | PLGPLATLMNA | |
| SCHEMBL3427792 | 0.87 | ESR1 (0.34) | — | |
| SCHEMBL927909 | 0.87 | ESR1 (0.34) | — | |
| Acetic Acid SCHEMBL2479593 | 0.82 | — | — | |
| SCHEMBL926893 | 0.79 | PLG (0.34) | PLGPLATLMNA | |
| SCHEMBL3425740 | 0.79 | PLG (0.34) | PLGPLATLMNA | |
| SCHEMBL3424858 | 0.77 | PLG (0.56) | PLGPLATLMNA | |
| SCHEMBL929414 | 0.77 | PLG (0.56) | PLGPLATLMNA | |
| Acetone SCHEMBL9562373 | 0.75 | — | — | |
| Acetic Acid SCHEMBL1058296 | 0.74 | POLB (0.34) | PLGPLATLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671191-B2 | Methods for preparing 2-alkynyladenosine derivatives | PGX HEALTH, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADENOSINE THERAPEUTICS, LLC | 2008-07-24 | — | — | US | disclosed |
| EP-1625139-A2 | METHODS FOR PREPARING 2-ALKYNYLADENOSINE DERIVATIVES | Bristol-Myers Squibb Pharma Company (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050033044-A1 | Methods for preparing 2-alkynyladenosine derivatives | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-02-10 | — | — | US | disclosed |
| WO-2004104017-A2 | METHODS FOR PREPARING 2-ALKYNYLADENOSINE DERIVATIVES | BRISTOL-MEYERS SQUIBB PHARMA COMPANY (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033044-A1 | Methods for preparing 2-alkynyladenosine derivatives | ADORA2A, ADORA3, ADORA1 | PLG 2990/4885PLAT 3969/4885LMNA 1134/4885 |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADORA2A, ADORA3, ADORA1 | PLG 2613/4885PLAT 3679/4885LMNA 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.